Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn's Disease: Results of a Decision Analysis

被引:14
|
作者
Ananthakrishnan, Ashwin N. [1 ,2 ]
Hur, Chin [1 ,2 ,3 ]
Korzenik, Joshua R. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Crohns & Colitis Ctr, Gastrointestinal Unit, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA
关键词
Crohn's disease; Certolizumab pegol; Natalizumab; Refractory disease; Surgery; Cost-effectiveness; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; COST-EFFECTIVENESS ANALYSIS; PRIOR INFLIXIMAB THERAPY; MAINTENANCE THERAPY; CLINICAL-RESPONSE; RANDOMIZED-TRIAL; MARKOV MODEL; ADALIMUMAB; INDUCTION; REMISSION;
D O I
10.1007/s10620-011-1896-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
A significant proportion of patients with Crohn's disease (CD) lose response to antibodies directed against tumor necrosis factor alpha (TNF). Prior TNF-antagonist failure is associated with lower rates of response to subsequent TNF-antagonist therapy. In patients failing two anti-TNF agents, a choice exists between using a third-anti-TNF therapy or natalizumab (NAT), an alpha-4 integrin inhibitor. A cost-effectiveness analysis comparing these competing strategies has not been performed. A decision analytic model was constructed to compare the performance of certolizumab pegol (CZP) versus NAT in patients with moderate to severe CD. Previously published estimates of efficacy of third-line anti-TNF therapy and NAT were used to inform the model. Costs were expressed in 2010 US dollars. A 1-year time frame was used for the analysis. In the base case estimate, use of NAT was only marginally more effective [0.71 vs. 0.70 quality adjusted life-years (QALYs)] than CZP but was expensive with an incremental cost-effectiveness ratio (ICER) of $381,678 per QALY gained. For CZP 2 months response rate of at least 24%, NAT had an ICER above the willingness-to-pay (WTP) threshold. The model was sensitive to the costs of both therapies; for all CZP costs below $2,300 per dose, NAT had higher ICER than the WTP threshold. Substituting adalimumab for CZP resulted in similar ICER estimates and thresholds for NAT use. In patients with moderate to severe CD failing two TNF-antagonists, using a third TNF-antagonist therapy appears to be a cost-effective strategy without significantly compromising treatment efficacy.
引用
收藏
页码:472 / 480
页数:9
相关论文
共 50 条
  • [1] Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn’s Disease: Results of a Decision Analysis
    Ashwin N. Ananthakrishnan
    Chin Hur
    Joshua R. Korzenik
    Digestive Diseases and Sciences, 2012, 57 : 472 - 480
  • [2] Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
    Sandborn, William J.
    Abreu, Maria T.
    D'Haens, Geert
    Colombel, Jean-Frederic
    Vermeire, Severine
    Mitchev, Krassimir
    Jamoul, Corinne
    Fedorak, Richard N.
    Spehlmann, Martina E.
    Wolf, Douglas C.
    Lee, Scott
    Rutgeerts, Paul
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (08) : 688 - 695
  • [3] Severe Crohn's disease symptoms are relieved by certolizumab pegol
    Feagan, Brian G.
    Coteur, Geoffroy
    Keininger, Doroth L.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S471 - S471
  • [4] Induction Therapy with Certolizumab Pegol in Patients with Moderate to Severe Crohn's Disease: A Placebo-Controlled Trial
    Sandborn, William
    Schreiber, Stefan
    Feagan, Brian
    Rutgeerts, Paul
    Younes, Ziad
    Bloomfield, Ralph
    Guzman, Juan Pablo
    D'Haens, Geert
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S419 - S419
  • [5] Certolizumab Pegol: A TNF-α Antagonist for the Treatment of Moderate-to-Severe Crohn's Disease
    Smith, Lisa S.
    Nelson, Michael
    Dolder, Christian R.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (02) : 333 - 342
  • [6] Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
    Wade, Janet R.
    Parker, Gerry
    Kosutic, Gordana
    Feagen, Brian G.
    Sandborn, William J.
    Laveille, Christian
    Oliver, Ruth
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (08): : 866 - 874
  • [7] Certolizumab pegol in Crohn's disease
    Blick, Stephanie K. A.
    Curran, Monique P.
    BIODRUGS, 2007, 21 (03) : 195 - 201
  • [8] CERTOLIZUMAB PEGOL IN CROHN'S DISEASE
    Patel, V. K.
    Ghosh, S.
    DRUGS OF TODAY, 2008, 44 (11) : 837 - 844
  • [9] Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn's Disease? A Meta-analysis of Controlled Clinical Trials
    Nikfar, Shekoufeh
    Ehteshami-Afshar, Solmaz
    Abdollahi, Mohammad
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2013, 15 (08) : 668 - 675
  • [10] Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
    Hebuterne, Xavier
    Lemann, Marc
    Bouhnik, Yoram
    Dewit, Olivier
    Dupas, Jean-Louis
    Mross, Michael
    D'Haens, Geert
    Mitchev, Krassimir
    Ernault, Etienne
    Vermeire, Severine
    Brixi-Benmansour, Hedia
    Moreels, Tom G.
    Mary, Jean-Yves
    Marteau, Philippe
    Colombel, Jean-Frederic
    GUT, 2013, 62 (02) : 201 - 208